Robert Casey actually said...
key among these challenges is reaching agreement with regulators about determining the appropriate efficacy endpoints to support approval of innovative medicines for rare diseases.
Context
Emphasizes the need for regulatory agreement on efficacy endpoints for rare disease drug approvals.
04/04/2022